Introduction: this prospective study defines the immune response to fresh arterial homograft replacement for graft infection. Material and methods: ten patients who underwent ABO-compatible homograft transplantation were studied for anti-HLA antibody production, and at early (1, 3, 7 days) and late (1, 3, 6, 12, 18, 24 months) follow-up. All patients received immunosuppressive treatment with cyclosporine (1-3 mg/kg/day). Abdominal CT scans were performed postoperatively at the 1, 6, 12, 18, 24 months follow-up. Results: preoperatively antibodies could not be detected. Postoperatively, as from 1st month post-transplant, a progressive increase in % PRA was observed in all patients, up to the 12th month of follow-up. Subsequently, at 18 and 36 months, a progressive decrease on % PRA was detected. Data showed that the recipient antibodies were directed against donor-specific antigens. During the immediate postoperative period (1, 3, 7 days) CD3- and CD4-positive T Lymphocytes slightly increased, whereas CD8 simultaneously decreased. Later, CD3 and CD4 progressively decreased and CD8 increased. Clinically, all patients were cured of infection at late follow-up. CT scans showed thickening of the aortic wall (range: 2.5-4.5 mm), with no signs of aneurysmal degeneration. Conclusions: fresh arterial homografts are immunogenic. Implanted homografts induce a strong anti-HLA antibody response, similar to chronic rejection, in spite of immunosuppressive treatment.
Mirelli, M., Stella, A., Faggioli, G.L., Scolari, M.P., Iannelli, S., Freyrie, A., et al. (1999). Immune response following fresh arterial homograft replacement for aortoiliac graft infection. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 18(5), 424-429 [10.1053/ejvs.1999.0936].
Immune response following fresh arterial homograft replacement for aortoiliac graft infection
Mirelli M.;Stella A.;Faggioli G. L.;Scolari M. P.;Freyrie A.;Buscaroli A.;Bonomini V.;D'Addato M.
1999
Abstract
Introduction: this prospective study defines the immune response to fresh arterial homograft replacement for graft infection. Material and methods: ten patients who underwent ABO-compatible homograft transplantation were studied for anti-HLA antibody production, and at early (1, 3, 7 days) and late (1, 3, 6, 12, 18, 24 months) follow-up. All patients received immunosuppressive treatment with cyclosporine (1-3 mg/kg/day). Abdominal CT scans were performed postoperatively at the 1, 6, 12, 18, 24 months follow-up. Results: preoperatively antibodies could not be detected. Postoperatively, as from 1st month post-transplant, a progressive increase in % PRA was observed in all patients, up to the 12th month of follow-up. Subsequently, at 18 and 36 months, a progressive decrease on % PRA was detected. Data showed that the recipient antibodies were directed against donor-specific antigens. During the immediate postoperative period (1, 3, 7 days) CD3- and CD4-positive T Lymphocytes slightly increased, whereas CD8 simultaneously decreased. Later, CD3 and CD4 progressively decreased and CD8 increased. Clinically, all patients were cured of infection at late follow-up. CT scans showed thickening of the aortic wall (range: 2.5-4.5 mm), with no signs of aneurysmal degeneration. Conclusions: fresh arterial homografts are immunogenic. Implanted homografts induce a strong anti-HLA antibody response, similar to chronic rejection, in spite of immunosuppressive treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.